• No results found

[NORMAL] Managing Research in Hospices

N/A
N/A
Protected

Academic year: 2021

Share "Managing Research in Hospices"

Copied!
42
0
0

Loading.... (view fulltext now)

Full text

(1)

Managing Research in Hospices

Paul Perkins

(2)

Why?

We need to know what the best treatments are for our patients and their families

(3)

Duty

We have a duty to contribute: Conducting research

Finding patients for researchers and singposting them

(4)

The Aim

Research is seen as core business

Think about mentioning it in leaflets or on your hospice website

(5)

Ideas

Journal clubs Read papers

Go to conferences

What’s important to your patients?

(6)

Talk to Management

Better patient care

Enhanced job satisfaction Staff retention

(7)

Build a team

You can’t do this alone – it’s not doable and it’s no fun

Find people locally

Contact national / international experts and see if they want to collaborate

(8)

Research Nurses

ESSENTIAL!!!

Ask management if they will appoint 1 part-time Look for a trust fund to support their

salary for the first year

Think about external studies e.g. drug company to help fund

(9)

Volunteer for studies

It doesn’t take long to get a reputation as a centre

Look on the UK Clinical Research Network Website

Ask colleagues in other units who are recruiting to recommend you

(10)

Sponsorship

All research needs a sponsor This isn’t just about funding

(11)

Sponsor Responsibilities

The governance of research from conception to final completion – design, management, finance

Sponsor has to satisfy itself that appropriate checks have been undertaken

(12)

Risks of Sponsorship

Financial – claims for damages to participants Legal – prosecution by Medicines and

Healthcare products Regulatory Agency (MHRA) (or other regulatory authority) for breach of Clinical Trials Regulations

Reputation – failure of the study, failure to meet required standards to satisfy MHRA auditors, or from prosecution

(13)

What a sponsor does

Risk assessment:

All responsibilities listed in the Research Governance

Framework and the Clinical Trials Regulations accepted Is this good science? Peer review

Competence of the Chief Investigator and host organisation

Appropriate training in research methods and Good Clinical Practice for members of the research team Audit and monitoring of the study

(14)

What a sponsor does

Legally responsible for some things:

Request clinical trial authorisation and ethics approval Allow inspection of premises by MHRA if required

Give notice of amendments to the protocol to MHRA and ethics committee

Give notice a trial has ended

Research Governance Framework (DH 2005)

(15)

What a sponsor does

Legally responsible for some things:

Keep records of all adverse events reported by investigators

Ensure recording and prompt reporting of suspected unexpected serious adverse reactions (SUSARs)

Ensure investigators (e.g. in other sites) are informed of SUSARs

Ensure all SUSARs entered into European database Provide annual list of SUSARs and a safety report

(16)

What a sponsor does

Responsible for ensuring indemnity is in place for the study

Research Governance Framework (DH 2005)

(17)

My advice

Don’t do it

(18)

Find a Sponsor

Go and talk to:

Your local NHS Trust R&D Management Team Local university

(19)

Find a Sponsor

(20)

Indemnity

There are questions about this on the ethics form:

What arrangements will be made for insurance and/or indemnity to meet the potential legal

liability of the sponsor for harm to participants arising from the research

management? design?

(21)

Indemnity

(22)

Indemnity

Talk to the hospice insurers about the kind of research you want to do

If what you are planning doesn’t vary much from standard practice there may not be any additional cost

(23)

Indemnity

(24)

Human Resources

Your staff engaged in research will need to

have this covered in their employment contract External staff will need some kind of access

(25)

Governance

How are you going to decide what to approve?

Is it the sort of thing we should be doing?

(26)

Standard Operating Procedures

Borrow them from someone else

Talk to your local NHS Trust research and development management team

(27)

Lawyers!!

There will need to be contracts E.g. for us:

Drug company – hospice

Hospice – Principal Investigator Drug company – hospital

(28)

Dedicated time

Ideally there should be time in job plans for research

(29)

Patience

(30)

Patience – Ascites Study

September 2008 protocol v1 May 2010 final protocol

April 2011 completed recruitment September 2011 submitted to BMJ December 2011 submitted to BJC March 2012 submitted to Pall Med July 2012 resubmitted to Pall Med

October 2012 resubmitted to Pall Med January 2013 resubmitted to Pall Med

January 2013 accepted for publication in Pall Med September 2013 published in Pall Med

(31)

Progress

Been consultant since 2004

No governance structures in place

Agreements to participate in trials – battles with lawyers

(32)

Recently

New charity-wide research policy issued Jan 2010

Research Governance Group looks at Sue Ryder research nationally – meets monthly

(33)

Role of RGG

Is the research relevant to the charity’s aims and objectives?

Has researcher followed correct processes?

Identify a list of requirements and ensure that they are complied with before research can go ahead

(34)

RGG - Membership

Quality Manager, Sue Ryder (Chair) Clinical Quality Lead /Lead Nurse Medical Director Sue Ryder

External member with research experience x 2 Service User Lead

Trustee (with research interest/experience) Legal Services Representative

Insurance Officer

Business Development Team Representative Neurological Care Representative x 2

Palliative Care Representative x2 Co-opted when required:

Researcher, Mentor, Human Resources, Research Interested Staff, Marcomms, Sue Ryder International, Finance

(35)

RGG – last meeting

Quality Manager, Sue Ryder (Chair)

Clinical Quality Lead /Lead Nurse Medical Director Sue Ryder

External member with research experience x 2 – just 1 Service User Lead

Trustee (with research interest/experience)

Legal Services Representative Insurance Officer

Business Development Team Representative Neurological Care Representative x 2

(36)

Achievements

Homegrown projects: Qualitative focus group and interview studies Questionnaire studies

RCT – acupressure Pilot RCT – drug

Drug company funded: RCTs

(37)

Achievements

2 fantastic part-time research nurses

1 has led on a project from protocol to publication

(38)

What we haven’t achieved

(39)

The future

We have achieved little so far

(40)

What you’ll need to make research

happen in your hospice

Management support

Local networks – collaborators, sponsors Legal support

Human resources support

Some kind of governance process / checklist Dedicated time

(41)

Useful references

Research Governance Toolkit

http://www.nischr-cancerrrg.org/research/

Payne S, Preston N, Turner M, Rolls L. Research in

(42)

Questions

References

Related documents

¤   Create special audiences in Facebook using your email6. list in order to target

• perform an independent review of the Kennedy Space Center (KSC) Quality Planning Requirements Document to address the quality assurance program and its administration,

Analysis of translation of specific TISU and non-TISU genes revealed that the effect of the glucose deprivation is quite similar to the WT MEFs, and TISU genes are refractory to

2016 (hereafter Paper I), with an analysis of the stellar populations within the full set of 23 in Edwards et al. Section 2 of this paper describes the sample selection,

In the Department of Psychology, we currently have 29 tenured or tenure-track faculty members (including a slot for our new chair, F11), about 20 adjunct faculty members, 119

This paper combines the multi-innovation identification theory [ 18 ], the auxiliary model identification idea [ 11 ] and the key-term separation principle [ 21–23 ] to study

The probability of an epidemic and expected fraction of the population infected during an epidemic for three classes networks: (N1) a completely undirected Poisson network with

In mid 2009, Osram inaugurated a 35 000 m² facility in Penang, Malaysia, to manufacture 4-inch- wafer-based indium gallium nitride semiconductor chips. These chips form the basis